The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction ...

The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE ®) to current standard-of ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Alibaba to sell stake in China's hypermarket chain Sun Art. Brand prescription drugs to rise an average 4.5% in 2025. Cybertruck blast driver identified; link to New Orleans attacker growing ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Alpelisib, we ran into a lot of toxicities, but they were all alpelisib toxicities. So a lower dose will be tested in the next cohort with elacestrant. And then capivasertib [Truqap] is in the early ...

Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...

Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE ®) to current standard-of ...